Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Third-line therapy for chronic myeloid leukemia: current status and future directions
Jorge E. Cortés, Fabian Lang
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance
Raquel Alves, Ana Cristina Gonçalves, Sergio Rutella, et al.
Cancers (2021) Vol. 13, Iss. 19, pp. 4820-4820
Open Access | Times Cited: 121
Organoids: The current status and biomedical applications
Siqi Yang, Hai‐Jie Hu, Heng‐Chung Kung, et al.
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 106
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
Andreas Hochhaus, Delphine Réa, Carla Boquimpani, et al.
Leukemia (2023) Vol. 37, Iss. 3, pp. 617-626
Open Access | Times Cited: 84
Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results
Jorge E. Cortés, Koji Sasaki, Dong‐Wook Kim, et al.
Leukemia (2024) Vol. 38, Iss. 7, pp. 1522-1533
Open Access | Times Cited: 22
Degraders upgraded: the rise of PROTACs in hematological malignancies
Joshua Casan, John F. Seymour
Blood (2024) Vol. 143, Iss. 13, pp. 1218-1230
Closed Access | Times Cited: 17
Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia
Jayastu Senapati, Elias Jabbour, Hagop M. Kantarjian, et al.
Leukemia (2022) Vol. 37, Iss. 1, pp. 5-17
Closed Access | Times Cited: 58
Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results
Michael J. Mauro, Timothy P. Hughes, Dong‐Wook Kim, et al.
Leukemia (2023) Vol. 37, Iss. 5, pp. 1048-1059
Open Access | Times Cited: 30
The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia
Mohamed El‐Tanani, Hamdi Nsairat, Ismail Matalka, et al.
Pathology - Research and Practice (2024) Vol. 254, pp. 155161-155161
Open Access | Times Cited: 15
Recent developments in receptor tyrosine kinase inhibitors: A promising mainstay in targeted cancer therapy
Rahul Kumar, Harsh Goel, Raghu Solanki, et al.
Medicine in Drug Discovery (2024) Vol. 23, pp. 100195-100195
Open Access | Times Cited: 9
Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukaemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1/2 trial
Jorge E. Cortés, Dong‐Wook Kim, Tapan Saikia, et al.
The Lancet Haematology (2025)
Closed Access | Times Cited: 1
Chronic myeloid leukemia stem cells: targeting therapeutic implications
Hanieh Mojtahedi, Niloufar Yazdanpanah, Nima Rezaei
Stem Cell Research & Therapy (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 51
Natural Killer Cell-Mediated Immunotherapy for Leukemia
Michaela Allison, Joel Mathews, Taylor Gilliland, et al.
Cancers (2022) Vol. 14, Iss. 3, pp. 843-843
Open Access | Times Cited: 37
Artificial Intelligence Assisted Pharmacophore Design for Philadelphia Chromosome-Positive Leukemia with Gamma-Tocotrienol: A Toxicity Comparison Approach with Asciminib
Muhammad Naveed, Noor Ul Ain, Tariq Aziz, et al.
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1041-1041
Open Access | Times Cited: 19
Chronic myeloid leukaemia: Biology and therapy
Yun Wang, Zhi-Jian Liang, Robert Peter Gale, et al.
Blood Reviews (2024) Vol. 65, pp. 101196-101196
Closed Access | Times Cited: 8
Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia
Alejandro Luna, Lucía Pérez‐Lamas, Concepción Boqué, et al.
Annals of Hematology (2022) Vol. 101, Iss. 10, pp. 2263-2270
Open Access | Times Cited: 28
Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors
Ehab Atallah, Michael J. Mauro, Andreas Hochhaus, et al.
Journal of Cancer Research and Clinical Oncology (2023) Vol. 149, Iss. 9, pp. 6247-6262
Open Access | Times Cited: 14
Safety and efficacy of flumatinib as later-line therapy in patients with chronic myeloid leukemia
Yunfan Yang, Yuntao Liu, Hui Sun, et al.
Haematologica (2024)
Open Access | Times Cited: 4
Potential Approaches Versus Approved or Developing Chronic Myeloid Leukemia Therapy
Emanuela Andretta, Caterina Costa, Consiglia Longobardi, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 24
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
Delphine Réa, Carla Boquimpani, Michael J. Mauro, et al.
Leukemia (2023) Vol. 37, Iss. 5, pp. 1060-1067
Open Access | Times Cited: 10
Exploring the significance of MDM2 gene promoter variants in chronic myeloid leukemia
María Fontecha, María del Rosario Anadón, Inés María Martínez Lahitou, et al.
Leukemia Research (2025) Vol. 149, pp. 107644-107644
Closed Access
CDK8/19 inhibition attenuates G1 arrest induced by BCR-ABL antagonists and accelerates death of chronic myelogenous leukemia cells
Alvina I. Khamidullina, Margarita A. Yastrebova, Alexandra V. Bruter, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
Investigating The Impact Of Homoharringtonine On K562 Cell Viability And ER Stress Pathways
Mingyang Wang, S.P. Zhao, Sarah Tan Si Yu, et al.
BIO Web of Conferences (2025) Vol. 163, pp. 03002-03002
Open Access
Utilization of Machine Learning in the Prediction, Diagnosis, Prognosis, and Management of Chronic Myeloid Leukemia
Fabio Stagno, Sabina Russo, Giuseppe Murdaca, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2535-2535
Open Access
Asciminib monotherapy in patients with chronic myeloid leukemia in chronic phase without BCR::ABL1T315I treated with at least 2 prior TKIs: Phase 1 final results
Andreas Hochhaus, Dong‐Wook Kim, Jorge E. Cortés, et al.
Leukemia (2025)
Open Access
Asciminib in combination with imatinib, nilotinib, or dasatinib in patients with chronic myeloid leukemia in chronic or accelerated phase: phase 1 study final results
Jorge E. Cortés, Fabian Lang, Delphine Réa, et al.
Leukemia (2025)
Open Access
Page 1 - Next Page

Scroll to top